Fed Circuit backs Eli Lilly in Apotex’s appeal over failed Alimta NDA
The US Court of Appeals for the Federal Circuit yesterday, December 21, upheldEli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
10 March 2026 The telehealth platform’s shares jumped more than 40% after the news that it will sell Ozempic and Wegovy—and no longer faces a lawsuit from the Danish pharma giant.
6 March 2026 With IWD approaching, WIPR urges practitioners to submit nominations for its Influential Women in IP list, recognising outstanding female leaders across the profession.
